124:@0.085929:0.957873:0.109689:0.957873:0.109689:0.938882:0.085929:0.938882:0.007346:0.007823:0.008591
5:@0.038824:0.435294:0.060302:0.435294:0.060302:0.387816:0.038824:0.387816:0.021478
CHAPTER 5:@0.117647:0.067219:0.190589:0.067219:0.190589:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008487
percentage of non-somatic (left) and somatic (right) SV calls kept (green) or removed (brown) in the pre-:@0.117647:0.118163:0.853053:0.118163:0.853053:0.101494:0.117647:0.101494:0.009413:0.007396:0.006089:0.007359:0.007396:0.009320:0.005360:0.007527:0.007900:0.007396:0.004408:0.008871:0.005080:0.004408:0.009488:0.008871:0.009618:0.006163:0.006443:0.008871:0.014381:0.007209:0.005267:0.004538:0.007359:0.004408:0.005678:0.004240:0.007396:0.005071:0.005071:0.005678:0.004408:0.007433:0.009488:0.009320:0.004408:0.006443:0.008871:0.014381:0.007209:0.005267:0.004538:0.007359:0.004408:0.005678:0.006387:0.004594:0.008124:0.009077:0.005267:0.005678:0.004408:0.008274:0.012345:0.004408:0.007450:0.007695:0.004408:0.004296:0.006275:0.004408:0.008404:0.007471:0.009039:0.005267:0.004408:0.005678:0.008068:0.006089:0.007452:0.007396:0.009618:0.005678:0.004408:0.008871:0.006387:0.004408:0.006089:0.007396:0.014308:0.008890:0.007881:0.007452:0.009320:0.004408:0.005678:0.008853:0.006089:0.008890:0.012046:0.009618:0.005678:0.004408:0.004594:0.009618:0.004408:0.005416:0.009247:0.007396:0.004408:0.009058:0.006089:0.007396:0.006163
filtering step for COLO829 and HGS-3. :@0.117647:0.132715:0.391388:0.132715:0.391388:0.116046:0.117647:0.116046:0.004650:0.004762:0.004015:0.005080:0.007396:0.006387:0.004594:0.009376:0.008068:0.003026:0.006146:0.005080:0.007471:0.009226:0.003026:0.004931:0.008871:0.006387:0.003026:0.012065:0.013130:0.009430:0.013428:0.008535:0.008535:0.008535:0.003026:0.007433:0.009488:0.009320:0.003026:0.013428:0.012831:0.008274:0.006163:0.008535:0.003679:0.003362
(C) :@0.391011:0.132715:0.418858:0.132715:0.418858:0.115425:0.391011:0.115425:0.006238:0.012084:0.006238:0.003287
Median percentage of non-somatic (left) and somatic (right) SV :@0.418523:0.132715:0.856355:0.132715:0.856355:0.116046:0.418523:0.116046:0.015520:0.007452:0.009320:0.004744:0.007433:0.009618:0.003026:0.009413:0.007396:0.006089:0.007359:0.007396:0.009320:0.005360:0.007527:0.007900:0.007396:0.003026:0.008871:0.005080:0.003026:0.009488:0.008871:0.009618:0.006163:0.006443:0.008869:0.014381:0.007211:0.005267:0.004538:0.007359:0.003026:0.005678:0.004240:0.007396:0.005071:0.005071:0.005678:0.003026:0.007433:0.009488:0.009320:0.003026:0.006443:0.008871:0.014381:0.007209:0.005267:0.004538:0.007359:0.003026:0.005678:0.006387:0.004594:0.008124:0.009077:0.005267:0.005678:0.003026:0.008274:0.012345:0.003362
calls kept (green) or removed (brown) by the Random Forest SV classifier for COLO829 and HGS-3. :@0.117647:0.147267:0.825952:0.147267:0.825952:0.130598:0.117647:0.130598:0.007452:0.007695:0.004408:0.004296:0.006275:0.004408:0.008404:0.007471:0.009039:0.005267:0.004408:0.005678:0.008068:0.006089:0.007452:0.007396:0.009618:0.005678:0.004408:0.008871:0.006387:0.004408:0.006087:0.007396:0.014308:0.008890:0.007881:0.007452:0.009320:0.004408:0.005678:0.008853:0.006089:0.008890:0.012046:0.009618:0.005678:0.004408:0.008871:0.007956:0.004408:0.005416:0.009245:0.007396:0.004408:0.011374:0.007433:0.009488:0.009264:0.008871:0.014437:0.004408:0.008741:0.008871:0.006089:0.007396:0.006145:0.005267:0.004408:0.008274:0.012345:0.004408:0.007174:0.004445:0.007601:0.006161:0.006221:0.004594:0.004650:0.004593:0.007396:0.006387:0.004408:0.004931:0.008871:0.006387:0.004408:0.012065:0.013130:0.009432:0.013428:0.008535:0.008535:0.008535:0.004408:0.007433:0.009488:0.009320:0.004408:0.013428:0.012831:0.008274:0.006163:0.008535:0.003679:0.003362
(D):@0.826943:0.147267:0.852941:0.147267:0.852941:0.129977:0.826943:0.129977:0.006238:0.013522:0.006238
 :@0.852941:0.147267:0.856302:0.147267:0.856302:0.130598:0.852941:0.130598:0.003362
Median percentage of non-somatic (left) and somatic (right) SV calls kept (green) or removed (brown) by :@0.117647:0.161819:0.856262:0.161819:0.856262:0.145151:0.117647:0.145151:0.015520:0.007452:0.009320:0.004744:0.007433:0.009618:0.004296:0.009413:0.007396:0.006089:0.007359:0.007396:0.009320:0.005360:0.007527:0.007900:0.007396:0.004296:0.008873:0.005080:0.004296:0.009488:0.008871:0.009618:0.006163:0.006443:0.008871:0.014381:0.007209:0.005267:0.004538:0.007359:0.004296:0.005678:0.004238:0.007396:0.005071:0.005071:0.005678:0.004296:0.007433:0.009488:0.009320:0.004296:0.006442:0.008871:0.014383:0.007209:0.005267:0.004537:0.007359:0.004296:0.005678:0.006387:0.004594:0.008122:0.009079:0.005267:0.005678:0.004296:0.008274:0.012345:0.004296:0.007452:0.007695:0.004408:0.004296:0.006275:0.004296:0.008404:0.007471:0.009039:0.005267:0.004296:0.005678:0.008068:0.006089:0.007452:0.007396:0.009618:0.005678:0.004296:0.008871:0.006387:0.004296:0.006089:0.007396:0.014306:0.008890:0.007881:0.007452:0.009320:0.004296:0.005678:0.008853:0.006089:0.008890:0.012046:0.009618:0.005678:0.004296:0.008871:0.007956:0.003362
the database filtering for COLO829 and HGS-3. :@0.117647:0.176371:0.455019:0.176371:0.455019:0.159702:0.117647:0.159702:0.005416:0.009245:0.007396:0.004099:0.009469:0.007209:0.005360:0.007452:0.009095:0.007601:0.006443:0.007396:0.004099:0.004650:0.004762:0.004015:0.005080:0.007396:0.006387:0.004594:0.009376:0.008068:0.004099:0.004931:0.008871:0.006387:0.004099:0.012065:0.013130:0.009432:0.013428:0.008535:0.008535:0.008535:0.004099:0.007433:0.009488:0.009320:0.004099:0.013428:0.012831:0.008274:0.006163:0.008535:0.003679:0.003362
(E) :@0.455755:0.176371:0.481697:0.176371:0.481697:0.159081:0.455755:0.159081:0.006238:0.010179:0.006238:0.003287
Median percentage of non-somatic (red) and somatic :@0.482418:0.176371:0.856310:0.176371:0.856310:0.159702:0.482418:0.159702:0.015520:0.007452:0.009320:0.004744:0.007433:0.009618:0.004099:0.009413:0.007396:0.006089:0.007359:0.007396:0.009320:0.005360:0.007527:0.007900:0.007396:0.004099:0.008871:0.005080:0.004099:0.009488:0.008871:0.009618:0.006163:0.006443:0.008871:0.014381:0.007209:0.005267:0.004538:0.007359:0.004099:0.005678:0.006089:0.007452:0.009320:0.005678:0.004099:0.007433:0.009488:0.009320:0.004109:0.006442:0.008871:0.014381:0.007211:0.005267:0.004537:0.007359:0.003362
SV (blue) calls in the complete SHARC output (left) and top 20 largest SVs (right) for COLO829 and HGS-:@0.117647:0.190923:0.853016:0.190923:0.853016:0.174255:0.117647:0.174255:0.008274:0.012345:0.003567:0.005678:0.008927:0.004015:0.009282:0.007396:0.005678:0.003567:0.007452:0.007693:0.004408:0.004296:0.006275:0.003567:0.004594:0.009618:0.003567:0.005416:0.009245:0.007396:0.003567:0.007359:0.008871:0.014138:0.009133:0.004240:0.007471:0.005080:0.007396:0.003567:0.007994:0.013148:0.012214:0.010888:0.012009:0.003567:0.008853:0.009058:0.005043:0.009039:0.009058:0.005267:0.003567:0.005678:0.004240:0.007396:0.005071:0.005071:0.005678:0.003567:0.007435:0.009488:0.009320:0.003567:0.005082:0.008853:0.009226:0.003567:0.008535:0.008535:0.003567:0.004445:0.007433:0.006238:0.007900:0.007396:0.006145:0.005267:0.003567:0.008274:0.012345:0.006275:0.003567:0.005678:0.006387:0.004594:0.008124:0.009077:0.005267:0.005678:0.003567:0.004931:0.008871:0.006387:0.003567:0.012065:0.013130:0.009432:0.013428:0.008535:0.008535:0.008535:0.003567:0.007433:0.009488:0.009320:0.003567:0.013428:0.012831:0.008274:0.006163
3.:@0.117647:0.205476:0.129861:0.205476:0.129861:0.188807:0.117647:0.188807:0.008535:0.003679
 (F):@0.129861:0.205476:0.156419:0.205476:0.156419:0.188185:0.129861:0.188185:0.004352:0.006238:0.009730:0.006238
 Total number of non-somatic (red) and somatic (blue) SV calls at each step of the pipeline for both :@0.156417:0.205476:0.856241:0.205476:0.856241:0.188807:0.156417:0.188807:0.004445:0.008890:0.008853:0.005360:0.007695:0.004296:0.004445:0.009320:0.009338:0.014231:0.009206:0.007396:0.006387:0.004445:0.008873:0.005080:0.004445:0.009490:0.008871:0.009618:0.006163:0.006442:0.008871:0.014381:0.007209:0.005267:0.004538:0.007359:0.004445:0.005678:0.006089:0.007452:0.009320:0.005678:0.004445:0.007433:0.009488:0.009320:0.004445:0.006443:0.008871:0.014381:0.007209:0.005267:0.004538:0.007359:0.004445:0.005678:0.008925:0.004015:0.009284:0.007396:0.005678:0.004445:0.008274:0.012345:0.004445:0.007452:0.007695:0.004408:0.004296:0.006275:0.004445:0.007209:0.005267:0.004445:0.007599:0.007601:0.007174:0.009376:0.004445:0.006146:0.005080:0.007469:0.009226:0.004445:0.008871:0.005080:0.004445:0.005416:0.009245:0.007396:0.004445:0.009058:0.004314:0.009413:0.007321:0.004296:0.004594:0.009488:0.007396:0.004445:0.004931:0.008871:0.006387:0.004445:0.009206:0.008853:0.005416:0.009376:0.003362
COLO829 and HGS-3. In low coverage subsets, all data points are shown and the square box represents the :@0.117647:0.220027:0.856421:0.220027:0.856421:0.203359:0.117647:0.203359:0.012065:0.013130:0.009432:0.013428:0.008535:0.008535:0.008535:0.003408:0.007433:0.009488:0.009320:0.003418:0.013428:0.012831:0.008274:0.006163:0.008535:0.003679:0.003418:0.005640:0.009618:0.003418:0.004240:0.008890:0.012046:0.003418:0.007359:0.008890:0.007881:0.007396:0.006462:0.007527:0.007900:0.007396:0.003418:0.006145:0.009282:0.008946:0.006443:0.007471:0.005267:0.006275:0.003679:0.003418:0.007695:0.004406:0.004296:0.003418:0.009469:0.007209:0.005360:0.007601:0.003418:0.009413:0.008871:0.004594:0.009320:0.005267:0.006275:0.003418:0.007433:0.006089:0.007396:0.003418:0.006182:0.009245:0.008890:0.012046:0.009618:0.003418:0.007433:0.009488:0.009320:0.003418:0.005416:0.009245:0.007396:0.003418:0.006443:0.008759:0.009488:0.007433:0.006089:0.007396:0.003418:0.009207:0.008853:0.008255:0.003418:0.006089:0.007471:0.009058:0.006089:0.007396:0.006443:0.007396:0.009320:0.005267:0.006275:0.003418:0.005416:0.009245:0.007396:0.003362
median value. RF: Random forest; DBFilter: Database filter.:@0.117647:0.234580:0.523259:0.234580:0.523259:0.217911:0.117647:0.217911:0.014306:0.007452:0.009320:0.004744:0.007433:0.009618:0.003362:0.008050:0.007695:0.004015:0.009282:0.007153:0.003679:0.003362:0.010944:0.009002:0.003679:0.003362:0.011372:0.007433:0.009490:0.009264:0.008871:0.014437:0.003362:0.004929:0.008871:0.006089:0.007396:0.006146:0.005267:0.003679:0.003362:0.012904:0.010197:0.009320:0.004706:0.004015:0.005080:0.007396:0.006649:0.003679:0.003362:0.013258:0.007209:0.005360:0.007452:0.009095:0.007601:0.006443:0.007396:0.003362:0.004650:0.004761:0.004017:0.005080:0.007396:0.005117:0.003679
Altogether, our SV filtering pipeline strongly enriches for true-positive somatic break-:@0.117647:0.273917:0.852941:0.273917:0.852941:0.253544:0.117647:0.253544:0.015066:0.004908:0.006209:0.011048:0.009656:0.009131:0.006620:0.011299:0.009039:0.006255:0.004497:0.005809:0.010820:0.011413:0.007807:0.005809:0.010112:0.015089:0.005809:0.005684:0.005821:0.004908:0.006209:0.009039:0.007807:0.005615:0.011459:0.009861:0.005809:0.011071:0.005273:0.011502:0.008948:0.005250:0.005615:0.011596:0.009039:0.005809:0.007512:0.006437:0.007442:0.010843:0.011459:0.009930:0.005182:0.009724:0.005809:0.009039:0.011756:0.007807:0.005547:0.008765:0.011299:0.009039:0.007670:0.005809:0.006026:0.010843:0.007807:0.005809:0.006437:0.007967:0.011345:0.009039:0.007533:0.011502:0.010957:0.007604:0.005271:0.006437:0.005547:0.009633:0.009039:0.005821:0.007873:0.010845:0.017574:0.008813:0.006437:0.005547:0.008994:0.005821:0.010820:0.007442:0.009288:0.009405:0.010503:0.007533
points and filters out the majority of false-positives and germline SVs. We demonstrate :@0.117647:0.294496:0.857009:0.294496:0.857009:0.274123:0.117647:0.274123:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.005045:0.009087:0.011596:0.011391:0.005045:0.005684:0.005821:0.004908:0.006209:0.009039:0.007624:0.007670:0.005045:0.010820:0.011071:0.006437:0.005045:0.006617:0.011302:0.009039:0.005045:0.017577:0.008811:0.005341:0.010843:0.007807:0.005273:0.006437:0.009724:0.005045:0.010843:0.006209:0.005045:0.006209:0.009405:0.005250:0.007875:0.009039:0.007533:0.011505:0.010957:0.007601:0.005273:0.006437:0.005545:0.009635:0.009039:0.007670:0.005045:0.009085:0.011596:0.011391:0.005045:0.009656:0.009039:0.007807:0.017759:0.005250:0.005615:0.011596:0.009039:0.005045:0.010112:0.015089:0.007670:0.004497:0.005045:0.018649:0.009039:0.005045:0.011322:0.009039:0.017485:0.010843:0.011619:0.007510:0.006437:0.007898:0.008811:0.006209:0.009039:0.004109
a total enrichment of true-positive somatic SV calls from 0.1% in the raw calls to 85% :@0.117647:0.315075:0.857048:0.315075:0.857048:0.294702:0.117647:0.294702:0.009291:0.005798:0.006209:0.010820:0.006551:0.009405:0.005250:0.005798:0.009039:0.011756:0.007807:0.005547:0.008765:0.011459:0.017485:0.009039:0.011391:0.006437:0.005798:0.010843:0.006209:0.005798:0.006437:0.007967:0.011345:0.009039:0.007533:0.011502:0.010959:0.007601:0.005271:0.006437:0.005547:0.009633:0.009039:0.005798:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.005798:0.010112:0.015089:0.005798:0.009108:0.009405:0.005387:0.005250:0.007670:0.005798:0.006414:0.007442:0.010843:0.017645:0.005798:0.010432:0.004497:0.010432:0.015043:0.005798:0.005615:0.011756:0.005798:0.006620:0.011299:0.009039:0.005798:0.007898:0.008925:0.014723:0.005798:0.009108:0.009402:0.005387:0.005250:0.007670:0.005798:0.006209:0.011048:0.005798:0.010432:0.010432:0.015043:0.004109
in the final Top20 ranked calls (17/20, COLO829, high coverage), 0.26% to 65% (13/20, :@0.117647:0.335653:0.856979:0.335653:0.856979:0.315280:0.117647:0.315280:0.005615:0.011756:0.004588:0.006617:0.011299:0.009039:0.004588:0.005684:0.005684:0.011687:0.009405:0.005250:0.004588:0.010866:0.010820:0.011276:0.010432:0.010432:0.004588:0.007898:0.009085:0.011870:0.010272:0.009108:0.011391:0.004588:0.009106:0.009405:0.005387:0.005250:0.007670:0.004588:0.006939:0.010432:0.010432:0.007099:0.010432:0.010432:0.004497:0.004588:0.014746:0.016047:0.011528:0.016412:0.010432:0.010432:0.010432:0.004497:0.004588:0.011459:0.005615:0.009930:0.011459:0.004588:0.008994:0.010866:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.006939:0.004497:0.004588:0.010432:0.004497:0.010432:0.010432:0.015043:0.004588:0.006209:0.011048:0.004588:0.010432:0.010432:0.015043:0.004588:0.006939:0.010432:0.010432:0.007099:0.010432:0.010432:0.004497:0.004109
HGS-3, high coverage), on average 0.18% to 41.7% (8.3/20, COLO829, low coverage :@0.117647:0.356232:0.857027:0.356232:0.857027:0.335859:0.117647:0.335859:0.016412:0.015682:0.010112:0.007533:0.010432:0.004497:0.007008:0.011459:0.005615:0.009927:0.011459:0.007008:0.008994:0.010863:0.009635:0.009039:0.007896:0.009199:0.009658:0.009039:0.006939:0.004497:0.007008:0.010845:0.011756:0.007008:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.007008:0.010432:0.004497:0.010432:0.010432:0.015043:0.007008:0.006209:0.011048:0.007008:0.010432:0.010432:0.004497:0.010432:0.015043:0.007008:0.006939:0.010432:0.004497:0.010432:0.007099:0.010432:0.010432:0.004497:0.007008:0.014744:0.016047:0.011528:0.016412:0.010432:0.010432:0.010432:0.004497:0.007008:0.005182:0.010866:0.014723:0.007008:0.008994:0.010866:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.004109
sets) and on average 0.49% to 64.2% (12.8/20, HGS-3, low coverage sets) (:@0.117647:0.376811:0.730215:0.376811:0.730215:0.356438:0.117647:0.356438:0.007875:0.009131:0.006437:0.007670:0.006939:0.003960:0.009087:0.011596:0.011391:0.003960:0.010843:0.011756:0.003972:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.003972:0.010432:0.004497:0.010432:0.010432:0.015043:0.003960:0.006209:0.011048:0.003972:0.010432:0.010432:0.004497:0.010432:0.015043:0.003960:0.006939:0.010432:0.010432:0.004497:0.010432:0.007099:0.010432:0.010432:0.004497:0.003960:0.016412:0.015682:0.010112:0.007533:0.010432:0.004497:0.003960:0.005182:0.010866:0.014723:0.003972:0.008994:0.010866:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.003972:0.007875:0.009128:0.006437:0.007670:0.006939:0.003960:0.006939
Figure 2F:@0.730173:0.376811:0.815043:0.376811:0.815043:0.355678:0.730173:0.355678:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.003881:0.010911:0.011893
). Of :@0.815036:0.376811:0.857060:0.376811:0.857060:0.356438:0.815036:0.356438:0.006939:0.004497:0.003972:0.016298:0.006209:0.004109
note, despite low coverage sequencing, each of the somatic SV calls identifies breakpoints :@0.117647:0.397389:0.857052:0.397389:0.857052:0.377017:0.117647:0.377017:0.011596:0.010820:0.006209:0.008743:0.004497:0.003333:0.011322:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.003333:0.005182:0.010866:0.014723:0.003333:0.008994:0.010866:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.003333:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009679:0.004497:0.003333:0.009288:0.009291:0.008768:0.011459:0.003333:0.010843:0.006209:0.003333:0.006620:0.011299:0.009039:0.003333:0.007875:0.010843:0.017579:0.008811:0.006437:0.005545:0.008994:0.003333:0.010112:0.015089:0.003333:0.009108:0.009405:0.005387:0.005250:0.007670:0.003333:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009039:0.007670:0.003333:0.010820:0.007442:0.009291:0.009402:0.010274:0.011502:0.010845:0.005615:0.011391:0.006437:0.007670:0.004109
at nucleotide resolution, providing immediate access to breakpoint PCR testing.:@0.117647:0.417968:0.785828:0.417968:0.785828:0.397595:0.117647:0.397595:0.008811:0.006437:0.004109:0.011391:0.011345:0.008765:0.005182:0.009108:0.010820:0.006437:0.005547:0.011322:0.009039:0.004109:0.007442:0.009039:0.007875:0.010934:0.004908:0.011071:0.006437:0.005547:0.010843:0.011756:0.004497:0.004109:0.011071:0.007442:0.010866:0.009838:0.005547:0.011391:0.005615:0.011457:0.009861:0.004109:0.005615:0.017645:0.017485:0.009108:0.011391:0.005798:0.008811:0.006209:0.009039:0.004109:0.009291:0.008994:0.008994:0.009039:0.007533:0.007670:0.004109:0.006209:0.011048:0.004109:0.010818:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.004109:0.012167:0.014678:0.013376:0.004109:0.006209:0.009039:0.007510:0.006437:0.005615:0.011459:0.009679:0.004497
Validation in tumor tissue from patients with ovarian and prostate cancer:@0.117647:0.475411:0.781623:0.475411:0.781623:0.452251:0.117647:0.452251:0.009288:0.010558:0.008691:0.004856:0.011081:0.009463:0.008616:0.004856:0.011256:0.011679:0.003984:0.004856:0.011679:0.003984:0.008616:0.011156:0.014817:0.011256:0.011231:0.003984:0.008616:0.004856:0.010409:0.010409:0.011156:0.009363:0.003984:0.008840:0.011076:0.011256:0.014817:0.003984:0.010110:0.009463:0.008616:0.004856:0.009363:0.011679:0.008516:0.010409:0.003735:0.015987:0.004856:0.008616:0.011579:0.003984:0.011104:0.009288:0.010558:0.011231:0.004856:0.010558:0.011679:0.003735:0.010558:0.011679:0.011231:0.003984:0.010733:0.011079:0.011256:0.010312:0.007518:0.009465:0.008616:0.009363:0.003984:0.010905:0.010558:0.011679:0.011007:0.009363:0.011231
Next, we tested the pipeline on four high-grade serous ovarian cancer (Ova1-4) and six :@0.117647:0.524978:0.856979:0.524978:0.856979:0.504605:0.117647:0.504605:0.015522:0.009108:0.010089:0.006437:0.004497:0.004725:0.014518:0.009039:0.004725:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.004725:0.006620:0.011299:0.009039:0.004725:0.011071:0.005273:0.011502:0.008948:0.005250:0.005615:0.011596:0.009039:0.004725:0.010843:0.011756:0.004725:0.006026:0.010820:0.011413:0.007807:0.004725:0.011459:0.005615:0.009927:0.011459:0.007533:0.009861:0.007898:0.009291:0.011322:0.009039:0.004725:0.007875:0.009039:0.007442:0.010820:0.011413:0.007670:0.004725:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.004725:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004725:0.006939:0.016890:0.009838:0.009291:0.010432:0.007533:0.010432:0.006939:0.004725:0.009085:0.011598:0.011391:0.004725:0.007601:0.005615:0.010089:0.004109
prostate cancer (Pros1-6) samples. We sequenced tumor DNA on one nanopore flow :@0.117647:0.545556:0.856965:0.545556:0.856965:0.525183:0.117647:0.525183:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.006391:0.009108:0.009085:0.011598:0.008994:0.009039:0.007807:0.006391:0.006939:0.011916:0.007442:0.010957:0.007670:0.010432:0.007533:0.010432:0.006939:0.006391:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.006391:0.018652:0.009039:0.006391:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.006391:0.006163:0.011413:0.017485:0.010843:0.007807:0.006391:0.015773:0.015408:0.014929:0.006391:0.010843:0.011756:0.006391:0.010843:0.011596:0.009039:0.006391:0.011687:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.006391:0.005638:0.005570:0.010866:0.014723:0.004109
cell per sample. The ovarian cancer samples and three prostate cancer samples (Pros1-3) :@0.117647:0.566135:0.856963:0.566135:0.856963:0.545762:0.117647:0.545762:0.008994:0.008948:0.005387:0.005250:0.004063:0.011505:0.009039:0.007807:0.004063:0.007944:0.009085:0.017280:0.011162:0.005182:0.008743:0.004497:0.004063:0.011470:0.011311:0.009039:0.004063:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.004063:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004063:0.007941:0.009085:0.017280:0.011162:0.005184:0.009039:0.007670:0.004063:0.009085:0.011596:0.011391:0.004063:0.006620:0.011459:0.007442:0.009108:0.009039:0.004063:0.011071:0.007442:0.010959:0.007510:0.006549:0.008811:0.006211:0.009039:0.004063:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004063:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004063:0.006939:0.011916:0.007442:0.010957:0.007670:0.010432:0.007533:0.010432:0.006939:0.004109
were sequenced on commercial ONT flow cells. For the ovarian cancer samples, we start-:@0.117647:0.586714:0.852941:0.586714:0.852941:0.566341:0.117647:0.566341:0.014518:0.009039:0.007442:0.009039:0.003287:0.007873:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.003287:0.010843:0.011756:0.003287:0.008994:0.010843:0.017645:0.017485:0.009039:0.007442:0.008994:0.005798:0.009405:0.005250:0.003287:0.016047:0.016230:0.013354:0.003287:0.005638:0.005570:0.010866:0.014723:0.003287:0.008994:0.008948:0.005387:0.005250:0.007670:0.004497:0.003287:0.010683:0.010845:0.007807:0.003287:0.006620:0.011299:0.009039:0.003287:0.010866:0.009838:0.009085:0.007807:0.005796:0.009085:0.011756:0.003287:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.003287:0.007944:0.009087:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.003287:0.014518:0.009039:0.003287:0.007510:0.006551:0.009085:0.007964:0.006483:0.007533
ed library preparation with minimally 1 µg of DNA. For the prostate cancer samples lim-:@0.117647:0.607292:0.852941:0.607292:0.852941:0.586919:0.117647:0.586919:0.009108:0.011391:0.003629:0.005250:0.005547:0.010820:0.007898:0.009085:0.008400:0.009724:0.003629:0.011071:0.007442:0.009131:0.011368:0.009085:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.003629:0.014723:0.005273:0.006620:0.011459:0.003629:0.017645:0.005615:0.011756:0.005615:0.017577:0.009402:0.005387:0.005182:0.009724:0.003629:0.010432:0.003629:0.010957:0.009861:0.003629:0.010843:0.006209:0.003629:0.015773:0.015408:0.014929:0.004497:0.003629:0.010683:0.010843:0.007807:0.003629:0.006620:0.011299:0.009039:0.003629:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.003629:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.003629:0.007944:0.009085:0.017280:0.011165:0.005182:0.009039:0.007670:0.003629:0.005250:0.005615:0.017711:0.007533
ited material was available, and we started library preparation with 250 ng of DNA. For :@0.117647:0.627871:0.857144:0.627871:0.857144:0.607498:0.117647:0.607498:0.005273:0.006209:0.009108:0.011391:0.004794:0.017577:0.008811:0.006209:0.009039:0.007807:0.005798:0.009405:0.005250:0.004794:0.014723:0.009291:0.007670:0.004794:0.008925:0.009838:0.009085:0.005752:0.005433:0.009108:0.010911:0.005182:0.008743:0.004497:0.004794:0.009085:0.011596:0.011391:0.004794:0.014520:0.009039:0.004794:0.007510:0.006551:0.009085:0.007967:0.006209:0.009108:0.011391:0.004794:0.005250:0.005547:0.010820:0.007896:0.009087:0.008398:0.009724:0.004794:0.011071:0.007442:0.009131:0.011365:0.009085:0.007898:0.008813:0.006437:0.005547:0.010843:0.011756:0.004794:0.014723:0.005273:0.006617:0.011459:0.004794:0.010432:0.010432:0.010432:0.004794:0.011461:0.009861:0.004794:0.010843:0.006209:0.004794:0.015773:0.015408:0.014929:0.004497:0.004794:0.010683:0.010843:0.007807:0.004109
one sample (Pros3), not enough sequencing data was produced to confidently detect so-:@0.117647:0.648450:0.852941:0.648450:0.852941:0.628077:0.117647:0.628077:0.010843:0.011596:0.009039:0.003995:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.003995:0.006939:0.011916:0.007442:0.010957:0.007670:0.010432:0.006939:0.004497:0.003995:0.011596:0.010820:0.006437:0.003995:0.009039:0.011596:0.010820:0.011413:0.009930:0.011459:0.003995:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.003995:0.011573:0.008811:0.006551:0.009291:0.003995:0.014723:0.009291:0.007670:0.003995:0.011071:0.007442:0.011276:0.011048:0.011345:0.008994:0.009108:0.011391:0.003995:0.006209:0.011048:0.003995:0.008994:0.010840:0.011756:0.005684:0.005618:0.011320:0.009039:0.011391:0.006622:0.005179:0.009724:0.003995:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.003995:0.007875:0.010957:0.007533
matic SVs and this sample was therefore excluded from all subsequent analyses (:@0.117647:0.669028:0.795879:0.669028:0.795879:0.648656:0.117647:0.648656:0.017577:0.008811:0.006437:0.005547:0.008994:0.004657:0.010112:0.015089:0.007670:0.004657:0.009085:0.011598:0.011391:0.004657:0.006620:0.011459:0.005615:0.007670:0.004657:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.004657:0.014723:0.009291:0.007670:0.004657:0.006620:0.011299:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.009039:0.004657:0.009108:0.009884:0.008765:0.004908:0.011345:0.011322:0.009108:0.011391:0.004657:0.006414:0.007442:0.010843:0.017645:0.004657:0.009405:0.005387:0.005250:0.004657:0.007510:0.011345:0.010934:0.007875:0.009108:0.010706:0.011345:0.009039:0.011391:0.006437:0.004657:0.009085:0.011687:0.009405:0.005182:0.009724:0.007875:0.009039:0.007670:0.004657:0.006939
Suppl. :@0.795989:0.669028:0.856957:0.669028:0.856957:0.647896:0.795989:0.647896:0.010455:0.011893:0.011733:0.011779:0.005659:0.005433:0.004018
Table 1:@0.117647:0.689607:0.182087:0.689607:0.182087:0.668474:0.117647:0.668474:0.011413:0.009679:0.011528:0.005935:0.009473:0.005501:0.010911
). Three additional prostate cancer samples (Pros4-6) were sequenced on ONT :@0.182079:0.689607:0.857021:0.689607:0.857021:0.669234:0.182079:0.669234:0.006939:0.004497:0.005615:0.011470:0.011470:0.007442:0.009108:0.009039:0.005615:0.009291:0.011322:0.011391:0.005271:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.005615:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.005615:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.005615:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.005615:0.006939:0.011916:0.007442:0.010957:0.007670:0.010432:0.007533:0.010432:0.006939:0.005615:0.014518:0.009039:0.007442:0.009039:0.005615:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.005615:0.010845:0.011756:0.005615:0.016047:0.016230:0.013354:0.004109
research prototype flow cells with higher sequencing sensitivity, thus requiring less DNA :@0.117647:0.710186:0.857048:0.710186:0.857048:0.689813:0.117647:0.689813:0.007442:0.009039:0.007875:0.009291:0.009085:0.007442:0.008765:0.011459:0.003744:0.011071:0.007442:0.010820:0.006209:0.010820:0.006437:0.009724:0.011505:0.009039:0.003744:0.005638:0.005570:0.010866:0.014723:0.003744:0.008994:0.008948:0.005387:0.005250:0.007670:0.003744:0.014723:0.005273:0.006620:0.011459:0.003744:0.011459:0.005615:0.009930:0.011299:0.009039:0.007807:0.003744:0.007875:0.009106:0.010706:0.011347:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.003744:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005545:0.009838:0.005273:0.006437:0.007989:0.004497:0.003744:0.006620:0.011094:0.011413:0.007670:0.003744:0.007442:0.009108:0.010703:0.011413:0.005615:0.007807:0.005615:0.011459:0.009861:0.003744:0.005182:0.009039:0.007533:0.007670:0.003744:0.015773:0.015408:0.014929:0.004109
input material. In these cases, library preparation was started with an average of 108 ng :@0.117647:0.730765:0.857096:0.730765:0.857096:0.710392:0.117647:0.710392:0.005615:0.011391:0.011048:0.011071:0.006437:0.004862:0.017579:0.008811:0.006209:0.009039:0.007807:0.005796:0.009405:0.004976:0.004497:0.004862:0.006894:0.011756:0.004862:0.006620:0.011302:0.009039:0.007873:0.009039:0.004862:0.009108:0.009291:0.007875:0.009039:0.007670:0.004497:0.004862:0.005250:0.005547:0.010820:0.007898:0.009085:0.008400:0.009724:0.004862:0.011071:0.007442:0.009131:0.011368:0.009085:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.004862:0.014723:0.009291:0.007670:0.004862:0.007510:0.006551:0.009085:0.007967:0.006209:0.009108:0.011391:0.004862:0.014723:0.005271:0.006620:0.011459:0.004862:0.009085:0.011756:0.004862:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.004862:0.010843:0.006209:0.004862:0.010432:0.010432:0.010432:0.004862:0.011459:0.009861:0.004109
(80-128 ng) of DNA and an average of 10 ng of library was loaded for sequencing (:@0.117647:0.751343:0.796114:0.751343:0.796114:0.730970:0.117647:0.730970:0.006939:0.010432:0.010432:0.007533:0.010432:0.010432:0.010432:0.003413:0.011459:0.009861:0.006939:0.003424:0.010843:0.006209:0.003424:0.015773:0.015408:0.014929:0.003424:0.009085:0.011596:0.011391:0.003424:0.009085:0.011756:0.003424:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.003424:0.010843:0.006209:0.003424:0.010432:0.010432:0.003424:0.011459:0.009861:0.003424:0.010843:0.006209:0.003424:0.005250:0.005547:0.010820:0.007898:0.009085:0.008400:0.009724:0.003424:0.014723:0.009291:0.007670:0.003424:0.005182:0.011139:0.009291:0.011322:0.009106:0.011391:0.003424:0.006026:0.010843:0.007807:0.003424:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.003424:0.006939
Suppl. :@0.795989:0.751343:0.856957:0.751343:0.856957:0.730210:0.795989:0.730210:0.010455:0.011893:0.011733:0.011779:0.005659:0.005433:0.004018
Table 1:@0.117647:0.771922:0.180409:0.771922:0.180409:0.750789:0.117647:0.750789:0.011413:0.009679:0.011528:0.005935:0.009473:0.003823:0.010911
). We obtained an average sequence coverage of 2.3x (range: 1.8 - 4.0) (:@0.180409:0.771922:0.764843:0.771922:0.764843:0.751549:0.180409:0.751549:0.006939:0.004497:0.003903:0.018649:0.009039:0.003903:0.010957:0.010797:0.006551:0.009085:0.005615:0.011596:0.009108:0.011391:0.003903:0.009085:0.011756:0.003903:0.008925:0.009635:0.009039:0.007896:0.009201:0.009653:0.009039:0.003903:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.009039:0.003903:0.008994:0.010866:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.003903:0.010843:0.006209:0.003903:0.010432:0.004497:0.010432:0.010089:0.003903:0.006939:0.007898:0.009085:0.011459:0.009656:0.009039:0.004497:0.003903:0.010432:0.004497:0.010432:0.003903:0.007533:0.003903:0.010432:0.004497:0.010432:0.006939:0.003903:0.006939
Figure 3A :@0.764933:0.771922:0.856959:0.771922:0.856959:0.750789:0.764933:0.750789:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.003823:0.010911:0.015089:0.004018
and Suppl. Table 1:@0.117647:0.792501:0.281931:0.792501:0.281931:0.771368:0.117647:0.771368:0.009656:0.012167:0.011870:0.004896:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.004896:0.011413:0.009679:0.011528:0.005935:0.009473:0.004908:0.010911
) and average read lengths of 7.8 Kbp (range: 4.2-16.3 Kbp) (:@0.281921:0.792501:0.794656:0.792501:0.794656:0.772128:0.281921:0.772128:0.006939:0.004999:0.009085:0.011596:0.011391:0.004999:0.008925:0.009635:0.009039:0.007898:0.009199:0.009656:0.009039:0.004999:0.007442:0.009291:0.009291:0.011391:0.004999:0.005182:0.009039:0.011459:0.009861:0.006617:0.011322:0.007670:0.004999:0.010843:0.006209:0.004999:0.010432:0.004497:0.010432:0.004999:0.014541:0.010797:0.011276:0.004999:0.006939:0.007896:0.009085:0.011461:0.009656:0.009039:0.004497:0.004999:0.010432:0.004497:0.010432:0.007533:0.010432:0.010432:0.004497:0.010432:0.004999:0.014541:0.010797:0.011276:0.006939:0.004999:0.006939
Figure :@0.794756:0.792501:0.856959:0.792501:0.856959:0.771368:0.794756:0.771368:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004018
3B and Suppl. Table 1:@0.117647:0.813079:0.308068:0.813079:0.308068:0.791947:0.117647:0.791947:0.010911:0.013765:0.004040:0.009656:0.012167:0.011870:0.004040:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.004040:0.011413:0.009679:0.011528:0.005935:0.009473:0.004040:0.010911
). The sequencing throughput was not affected by the lower DNA :@0.308072:0.813079:0.857035:0.813079:0.857035:0.792706:0.308072:0.792706:0.006939:0.004497:0.004132:0.011470:0.011313:0.009039:0.004132:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004132:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011094:0.011048:0.011071:0.006437:0.004132:0.014723:0.009291:0.007670:0.004132:0.011596:0.010820:0.006437:0.004132:0.009085:0.005969:0.005787:0.009108:0.009108:0.006209:0.009108:0.011391:0.004132:0.010843:0.009724:0.004132:0.006620:0.011299:0.009039:0.004132:0.005182:0.010866:0.014518:0.009039:0.007807:0.004132:0.015773:0.015408:0.014929:0.004109
input when using the high-sensitivity prototype flow cells. (:@0.117647:0.833658:0.614079:0.833658:0.614079:0.813285:0.117647:0.813285:0.005615:0.011391:0.011048:0.011071:0.006437:0.004109:0.014792:0.011299:0.009039:0.011756:0.004109:0.011413:0.007601:0.005615:0.011459:0.009861:0.004109:0.006617:0.011302:0.009039:0.004109:0.011459:0.005615:0.009927:0.011459:0.007533:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009838:0.005273:0.006437:0.009724:0.004109:0.011069:0.007442:0.010822:0.006207:0.010822:0.006437:0.009724:0.011502:0.009039:0.004109:0.005638:0.005570:0.010866:0.014723:0.004109:0.008994:0.008948:0.005387:0.005250:0.007670:0.004497:0.004109:0.006939
Suppl. Table 1:@0.614078:0.833658:0.738002:0.833658:0.738002:0.812525:0.614078:0.812525:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.004018:0.011413:0.009679:0.011525:0.005935:0.009473:0.004018:0.010911
).:@0.738003:0.833658:0.749439:0.833658:0.749439:0.813285:0.738003:0.813285:0.006939:0.004497
Following the lenient SV calling, pre-filtering, RF classification, the database filtering and :@0.117647:0.854237:0.857118:0.854237:0.857118:0.833864:0.117647:0.833864:0.010683:0.010934:0.005387:0.005182:0.010866:0.014723:0.005615:0.011459:0.009861:0.003447:0.006620:0.011299:0.009039:0.003447:0.005182:0.009039:0.011756:0.005547:0.009039:0.011391:0.006437:0.003447:0.010112:0.015089:0.003447:0.009108:0.009402:0.005387:0.005250:0.005615:0.011459:0.009679:0.004497:0.003447:0.011069:0.007444:0.009039:0.007533:0.005684:0.005819:0.004908:0.006209:0.009039:0.007807:0.005615:0.011459:0.009679:0.004497:0.003447:0.013376:0.011276:0.003447:0.008765:0.005433:0.009291:0.007533:0.007601:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.003447:0.006620:0.011299:0.009039:0.003447:0.011573:0.008811:0.006551:0.009108:0.011117:0.009291:0.007875:0.009039:0.003447:0.005684:0.005821:0.004908:0.006209:0.009039:0.007807:0.005615:0.011459:0.009861:0.003447:0.009087:0.011596:0.011391:0.004109
ranking steps, an average 2.8% (range of 1.0%-4.4%) of SVs per sample were retained :@0.117647:0.874815:0.857098:0.874815:0.857098:0.854442:0.117647:0.854442:0.007898:0.009085:0.011870:0.010706:0.005615:0.011459:0.009861:0.006437:0.007510:0.006209:0.009131:0.011185:0.007670:0.004497:0.006437:0.009085:0.011756:0.006437:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.006437:0.010432:0.004497:0.010432:0.015043:0.006437:0.006939:0.007898:0.009085:0.011459:0.009656:0.009039:0.006437:0.010840:0.006209:0.006437:0.010432:0.004497:0.010432:0.015043:0.007533:0.010432:0.004497:0.010432:0.015043:0.006939:0.006437:0.010843:0.006209:0.006437:0.010112:0.015089:0.007670:0.006437:0.011505:0.009039:0.007807:0.006437:0.007944:0.009085:0.017280:0.011162:0.005184:0.009039:0.006437:0.014518:0.009039:0.007442:0.009039:0.006437:0.007442:0.009131:0.006551:0.009085:0.005615:0.011596:0.009108:0.011391:0.004109
(:@0.117647:0.895394:0.124586:0.895394:0.124586:0.875021:0.117647:0.875021:0.006939
Figure 3C:@0.124586:0.895394:0.215163:0.895394:0.215163:0.874261:0.124586:0.874261:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.006711:0.010911:0.014769
). We performed breakpoint PCR assays on lymphocyte and tumor DNA :@0.215154:0.895394:0.856970:0.895394:0.856970:0.875021:0.215154:0.875021:0.006939:0.004497:0.006848:0.018649:0.009039:0.006848:0.011502:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.006848:0.010820:0.007442:0.009288:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.006848:0.012167:0.014678:0.013376:0.006848:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.006848:0.010843:0.011756:0.006848:0.005182:0.009724:0.017280:0.011162:0.011299:0.011276:0.009382:0.009724:0.006209:0.009039:0.006848:0.009085:0.011596:0.011391:0.006848:0.006163:0.011413:0.017485:0.010843:0.007807:0.006848:0.015773:0.015408:0.014929:0.004109
for the top 20 ranked SVs and validated an average of 10 (50%, range 25-80%) somatic :@0.117647:0.915973:0.856956:0.915973:0.856956:0.895600:0.117647:0.895600:0.006026:0.010843:0.007807:0.005250:0.006620:0.011299:0.009039:0.005250:0.006209:0.010820:0.011276:0.005250:0.010432:0.010432:0.005250:0.007896:0.009085:0.011870:0.010272:0.009108:0.011391:0.005250:0.010112:0.015089:0.007670:0.005250:0.009085:0.011596:0.011391:0.005250:0.009838:0.009402:0.005250:0.005547:0.011573:0.008811:0.006209:0.009108:0.011391:0.005250:0.009085:0.011756:0.005250:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.005250:0.010845:0.006209:0.005250:0.010432:0.010432:0.005250:0.006939:0.010432:0.010432:0.015043:0.004497:0.005250:0.007898:0.009085:0.011459:0.009656:0.009039:0.005250:0.010432:0.010432:0.007533:0.010432:0.010432:0.015043:0.006939:0.005250:0.007873:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004109